logo
Product categories

EbookNice.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link.  https://ebooknice.com/page/post?id=faq


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookNice Team

Phase 1/2a clinical trial of hESC-derived dopamineprogenitors in Parkinson’s disease by Jin Woo Chang & Han Kyu Na & Kyung Won Chang & Chan Wook Park & Do-Hun Kim & Sanghyun Park & Chul-Yong Park & Jang Hyeon Eom & Seung Taek Nam & Ki-Sang Jo & Mi-Young Jo & Sung Kyoung Choi & Hye-Jin Hur & Sarang Kim & Minseok Kim & Dae-Sung Kim &... instant download

  • SKU: EBN-239915954
Zoomable Image
$ 32 $ 40 (-20%)

Status:

Available

0.0

0 reviews
Instant download (eBook) Phase 1/2a clinical trial of hESC-derived dopamineprogenitors in Parkinson’s disease after payment.
Authors:Jin Woo Chang & Han Kyu Na & Kyung Won Chang & Chan Wook Park & Do-Hun Kim & Sanghyun Park & Chul-Yong Park & Jang Hyeon Eom & Seung Taek Nam & Ki-Sang Jo & Mi-Young Jo & Sung Kyoung Choi & Hye-Jin Hur & Sarang Kim & Minseok Kim & Dae-Sung Kim &...
Pages:updating ...
Year:2025
Publisher:The Authors
Language:english
File Size:8.46 MB
Format:pdf
Categories: Ebooks

Product desciption

Phase 1/2a clinical trial of hESC-derived dopamineprogenitors in Parkinson’s disease by Jin Woo Chang & Han Kyu Na & Kyung Won Chang & Chan Wook Park & Do-Hun Kim & Sanghyun Park & Chul-Yong Park & Jang Hyeon Eom & Seung Taek Nam & Ki-Sang Jo & Mi-Young Jo & Sung Kyoung Choi & Hye-Jin Hur & Sarang Kim & Minseok Kim & Dae-Sung Kim &... instant download

Cell, Corrected proof. doi:10.1016/j.cell.2025.09.010

Parkinson’s disease (PD) has long been considered an appropriate candidate for cell replacement therapy. Wegenerated high-purity dopaminergic progenitors (A9-DPCs) from human embryonic stem cells and evaluatedtheir safety and exploratory efficacy in a single-center, open-label, dose-escalation phase 1/2a trial(NCT05887466) for PD patients. Twelve patients with moderate-to-severe PD received bilateral putamen transplantation of low-dose (3.15 million cells; n = 6) or high-dose (6.30 million cells; n = 6) A9-DPC with immunosuppression. No dose-limiting toxicities or graft-related adverse events were observed. At 12 months, off-medication Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores andHoehn and Yahr stage improved, with greater motor improvements in the high-dose group. Dopamine transporter positron emission tomography (PET) imaging showed increased posterior putamen uptake with greateruptake in the high-dose group aftertransplantation, supporting graft survival. These findings indicate that bilateral transplantation of A9-DPC is safe and may improve parkinsonian motor symptoms in patients with PD.

*Free conversion of into popular formats such as PDF, DOCX, DOC, AZW, EPUB, and MOBI after payment.

Related Products